.

Dr. Steven A. Greenberg

Site presented by Bill Tillier.

.

.

Dr. Stephen Greenberg of Harvard, Cambridge, MA

Recent Work

Inclusion Body Myositis
Greenberg, S. A. (2016). Inclusion Body Myositis. Continuum (Minneapolis, Minn.), 22(6, Muscle and Neuromuscular Junction Disorders), 1871-1888. http://doi.org/10.1212/01.CON.0000511071.58338.1e
Summary: IBM has high unmet medical need. Advances in the mechanistic understanding of IBM as an autoimmune disease will drive effective therapeutic approaches. The identification of a B-cell pathway has resulted in the first identification of an IBM autoantigen and emphasized its status as an autoimmune disease. The recognition that large granular lymphocyte CD8+ T-cell expansions are present in both blood and muscle provides additional biomarkers for IBM and suggests a mechanistic relationship to the neoplastic disease T-cell large granular lymphocytic leukemia.

Cytotoxic T cells go awry in inclusion body myositis
An editorial by Reinhard Hohlfeld
Hohlfeld, R., & Schulze-Koops, H. (2016). Cytotoxic T cells go awry in inclusion body myositis. Brain, 139(5), 1312-1314. http://doi.org/10.1093/brain/aww053

Association of inclusion body myositis with T cell large granular lymphocytic leukaemia
Greenberg, S. A., Pinkus, J. L., Amato, A. A., Kristensen, T., & Dorfman, D. M. (2016). Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain, 139(5), 1348-1360. http://doi.org/10.1093/brain/aww024

Discussion of the Above Paper on Sporadic Inclusion Body Myositis.

ANTI- C N1A ANTIBODIES IN SOUTH AUSTRALIAN PATIENTS WITH INCLUSION BODY MYOSITIS
Limaye, V. S., Lester, S., Blumbergs, P., & Greenberg, S. A. (2016). Anti- C N1A antibodies in South Australian patients with inclusion body myositis. Muscle & Nerve, 53(4), 654-655. http://doi.org/10.1002/mus.24989

The Inclusion Body Myositis Foundation (IBMF)
Steven A. Greenberg, MD, Director
http://www.ibmfoundation.org/